Attention-Deficit/Hyperactivity Disorder (ADHD) — Diagnosis & Management

Key Points

• ADHD diagnosis requires DSM-5 criteria and impairment in ≥2 settings.
• Rule out learning disorders, sleep disorders, mood/anxiety disorders, thyroid abnormalities, and substance misuse.
• Stimulants are first-line for most patients ≥6 years old.
• Behavioral therapy is first-line for preschool-aged children.
• Monitor growth, cardiovascular parameters, and mental health during treatment.
• Neurodevelopmental disorder characterized by developmentally inappropriate inattention, hyperactivity, and impulsivity; diagnose using DSM-5 criteria with symptoms present in ≥2 settings, impairing function, and beginning in childhood; management includes behavioral therapy, environmental supports, and stimulant or non-stimulant pharmacotherapy tailored to age, comorbidities, and functional goals.
• ADHD diagnosis requires developmentally inappropriate symptoms in more than one setting with functional impairment and exclusion of important mimics. Treatment combines behavioral/educational supports and, when indicated, stimulant or nonstimulant medication with monitoring of response, growth, cardiovascular effects, sleep, and misuse risk.
• Base the urgent pathway on physiologic severity and red flags, not on the diagnostic label alone.

Algorithm

1. Identify inattentive and/or hyperactive-impulsive symptoms.
2. Obtain collateral history (parents, caregivers, teachers, partners, workplace).
3. Assess for comorbid psychiatric, developmental, and medical conditions.
4. Exclude mimics (sleep disorders, thyroid dysfunction, mood disorders, substance use).
5. Apply DSM-5 criteria and confirm functional impairment in ≥2 settings.
6. Initiate behavioral and/or pharmacologic therapy depending on age and severity.
7. Monitor response, tolerability, academic/work functioning, and comorbidities.
8. Reassess after the first major intervention and escalate if the objective treatment target is not improving.

Clinical Synopsis & Reasoning

ADHD is a chronic neurodevelopmental disorder presenting with patterns of inattention and/or hyperactivity-impulsivity that interfere with functioning or development. Diagnosis is clinical using DSM-5 criteria, requiring ≥6 symptoms (or ≥5 for adults), impairment across ≥2 settings, onset before age 12, and exclusion of mimics such as learning disorders, sleep disorders, anxiety, depression, thyroid disease, and substance use. Core evaluation includes detailed history, collateral information, school/occupational reports, and screening for comorbidities including ODD, learning disorders, mood and anxiety disorders, and autism spectrum disorder.

Psychiatric and neurobehavioral emergencies require an immediate safety assessment, a search for toxicologic, neurologic, infectious, endocrine, and medication-related causes, and a focused evaluation of autonomic findings, cognition, agitation, rigidity, clonus, tremor, withdrawal risk, and capacity. A psychiatric label should never substitute for evaluating an acute change in physiology or mental status.

Escalation findings include severe autonomic instability, hyperthermia, seizure, delirium, severe rigidity, escalating agitation with imminent danger, respiratory compromise after sedation, severe withdrawal, suicidal or violent behavior, or a toxicologic syndrome with progressive organ injury.

For Attention-Deficit/Hyperactivity Disorder (ADHD) — Diagnosis & Management, the differential should remain mechanistic and deliberately short. The clinician should identify the one or two alternatives that would change immediate management, then choose tests that discriminate among those possibilities. A familiar diagnosis should not be allowed to explain a new objective abnormality automatically. If the time course, severity, examination, or measured physiology does not fit the presumed process, reopen the differential before simply adding treatment.

Testing should be question-driven. High-yield studies in the source article include Clinical interview + DSM-5 symptom checklist, Collateral reports (parent, teacher, employer), Screening for comorbidities, Sleep assessment, Thyroid studies (TSH) as indicated. Each study should confirm the syndrome, identify etiology, quantify severity, detect a complication, or establish a safe baseline for treatment. Serial data are most useful when the trajectory changes management; broad low-yield testing can create incidental findings that distract from the decision at hand.

Interpret diagnostic results in the context of pretest probability and the limitations of the test. A negative result is reassuring only when the modality can exclude the suspected process at that stage, and a positive result matters only when it fits the phenotype. The working diagnosis should explain the symptoms, objective abnormalities, and time course together. Document the finding that most strongly supports the leading diagnosis, the dangerous alternative that remains, and the result or change that would cause the plan to pivot.

Separate diagnosis from severity. Two patients with Attention-Deficit/Hyperactivity Disorder (ADHD) — Diagnosis & Management may require different care because of age, pregnancy, organ reserve, immune status, anatomy, comorbidity, or a complication. The practical goal is to place the patient on the correct risk and management branch while preserving the option to reassess as new data arrive. Topic-specific branches in the source material include Inattention: ≥6 symptoms (≥5 for adults) for ≥6 months, inconsistent with developmental level; Hyperactivity/Impulsivity: ≥6 symptoms (≥5 for adults) for ≥6 months; Additional Requirements: Symptoms present before age 12, in ≥2 settings, causing impairment, not better explained by another disorder. A high-yield implementation point is: ADHD diagnosis requires developmentally inappropriate symptoms in more than one setting with functional impairment and exclusion of important mimics. Treatment combines behavioral/educational supports and, when indicated, stimulant or nonstimulant medication with monitoring of response, growth, cardiovascular effects, sleep, and misuse risk.

A useful decision architecture is to separate four questions: Is there an immediate threat that must be treated before the diagnosis is complete? What single finding most strongly establishes the working diagnosis? What finding measures severity or predicts deterioration? What intervention actually changes the underlying mechanism rather than only improving a symptom or number? Keeping those questions separate prevents common errors such as ordering a definitive test before stabilization, treating a laboratory value without treating its cause, or continuing empiric therapy after the data point elsewhere.

Monitoring should be chosen for the complication most likely to change the next decision in Attention-Deficit/Hyperactivity Disorder (ADHD) — Diagnosis & Management. Vital signs, mental status, urine output, oxygen requirement, pain pattern, ECG, laboratory trajectory, or focused repeat examination may be more informative than repeating a broad panel. The reassessment interval should shorten when the disease can deteriorate rapidly or when treatment itself can produce important toxicity. A stable patient can tolerate staged evaluation; an unstable patient needs parallel evaluation and treatment with explicit handoff of what remains unresolved.

Special populations can change both presentation and treatment thresholds. Pregnancy, advanced age, childhood, frailty, immunosuppression, kidney or liver dysfunction, anticoagulation, and major cardiovascular or pulmonary disease may alter symptoms, drug choice, dosing, imaging strategy, procedural risk, and disposition. Medication reconciliation should specifically look for agents that can precipitate the syndrome, mask its severity, interact with treatment, or require temporary interruption.

Communication is part of diagnostic safety. When transferring care, state the leading diagnosis, the evidence supporting it, the dangerous alternative that is not fully excluded, the treatment already given, the response observed, and the next trigger for escalation. This is especially important when a patient moves from the emergency department to a ward, ICU, procedure area, operating room, or outside referral center, because time-sensitive decisions are often lost at transitions rather than during the initial assessment.

Treatment Strategy & Disposition

Management integrates behavioral, educational, and pharmacologic strategies. For preschool children, behavior therapy is first line. For school-age children, adolescents, and adults, stimulants (methylphenidate or amphetamine formulations) are first-line, with non-stimulants (atomoxetine, guanfacine ER, clonidine ER, bupropion) used based on tolerability, comorbidities, or contraindications. Coordinate with schools/employers for structured support and academic accommodations. Monitor growth, appetite, sleep, blood pressure, heart rate, and psychiatric symptoms longitudinally.

Use verbal de-escalation and environmental modification first when feasible, then disease-specific medication with explicit monitoring for airway, blood pressure, QT, temperature, and oversedation. Toxicologic syndromes require withdrawal of the offending drug and supportive care; alcohol withdrawal requires adequately dosed GABAergic therapy and escalation when symptoms are refractory.

Relevant therapeutic tools in this article include Methylphenidate formulations, Amphetamine formulations, Atomoxetine, Guanfacine ER, Clonidine ER. Their presence in a table does not mean every patient should receive every option. Match treatment to the indication, contraindications, organ function, interaction profile, and the clinical endpoint that will define success.

After the first meaningful intervention, reassess the physiologic or functional target rather than assuming that treatment should continue automatically. If the response is poorer than expected, revisit diagnosis, treatment delivery, adherence or access, procedural success when relevant, and the possibility of a complication. Escalation should be tied to predefined failure criteria such as worsening hemodynamics, progressive organ dysfunction, persistent severe symptoms, new neurologic findings, or inability to achieve source control.

Disposition for Attention-Deficit/Hyperactivity Disorder (ADHD) — Diagnosis & Management should reflect instability, monitoring needs, treatment intensity, and the likelihood of sudden deterioration. ICU or specialty-unit care is appropriate when continuous organ support, invasive monitoring, frequent rescue treatment, or an urgent procedure is required. Stable patients still need a clear follow-up interval, explicit return precautions, and a plan for unresolved diagnostic uncertainty.

Prevention and recurrence reduction belong in the treatment plan. Review precipitating medications and exposures, chronic disease control, adherence barriers, vaccination or infection-prevention needs when relevant, rehabilitation, nutrition, and the patient’s ability to obtain follow-up care. The discharge plan should state what is complete, what remains pending, and exactly which new symptom or objective change warrants urgent reassessment.

Therapeutic sequencing matters. Stabilization, definitive therapy, and prevention are related but not interchangeable phases. A rescue intervention may buy time without correcting the cause; a definitive procedure may be ineffective if the patient is not physiologically prepared; and long-term prevention should not distract from an unresolved acute threat. The record should therefore identify which phase the patient is in and the endpoint required before moving to the next one.

Medication and procedure safety should be revisited after every major change in physiology. Renal or hepatic dysfunction, electrolyte shifts, bleeding risk, pregnancy, drug interactions, QT effects, sedation, airway risk, and changes in perfusion can convert an initially reasonable option into a poor one. When multiple therapies are possible, prefer the option that addresses the mechanism with the lowest foreseeable burden for that patient and that can be monitored reliably in the available care setting.

Treatment failure should be defined before it occurs. Persistent instability, progression of organ dysfunction, failure of a key laboratory or clinical marker to improve, worsening imaging, recurrent symptoms after a temporary response, or inability to achieve source control should trigger a new branch rather than indefinite repetition of the same therapy. That branch may be a second-line drug, invasive procedure, surgery, transfer, or reconsideration of the diagnosis.

Management Notes

Use the structured sections above as a clinical reference, not as a rigid protocol. Individual management for Attention-Deficit/Hyperactivity Disorder (ADHD) — Diagnosis & Management depends on age, pregnancy status when relevant, organ function, comorbidity, anatomy, contraindications, local resources, and patient preferences. Topic-specific source anchors include: Inattention: ≥6 symptoms (≥5 for adults) for ≥6 months, inconsistent with developmental level; Hyperactivity/Impulsivity: ≥6 symptoms (≥5 for adults) for ≥6 months; Additional Requirements: Symptoms present before age 12, in ≥2 settings, causing impairment, not better explained by another disorder. A high-yield implementation point is: ADHD diagnosis requires developmentally inappropriate symptoms in more than one setting with functional impairment and exclusion of important mimics. Treatment combines behavioral/educational supports and, when indicated, stimulant or nonstimulant medication with monitoring of response, growth, cardiovascular effects, sleep, and misuse risk. If the symptoms, examination, testing, and expected treatment response do not align, reopen the diagnosis before simply escalating the same therapy.

Epidemiology / Risk Factors

• Affects approximately 5–7% of children globally and persists into adulthood in ~60% of cases.
• High heritability (~70–80%).
• Commonly coexists with learning disorders, anxiety, depression, and sleep disorders.
• Risk for Attention-Deficit/Hyperactivity Disorder (ADHD) — Diagnosis & Management is modified by age, comorbidity, medication or exposure history, and the precipitating illness or anatomic substrate.
• Epidemiologic risk changes pretest probability but does not replace direct assessment of severity and objective findings.

Investigations

DSM-5 Diagnostic Criteria Overview

Pharmacology

Prognosis / Complications

• Symptoms often persist but can be effectively managed with structured supports and medications.
• Untreated ADHD increases risk of academic underachievement, occupational impairment, accidents, and mood disorders.
• Early treatment improves long-term academic and psychosocial functioning.
• Outcome depends on severity at recognition, speed of effective treatment, baseline organ reserve, and whether definitive control of the underlying process is achieved.
• Persistent organ dysfunction, recurrent instability, or failure of the expected treatment response identifies a higher-risk trajectory.

Patient Education / Counseling

• Explain that ADHD is a neurodevelopmental disorder—not a result of poor effort or parenting.
• Discuss medication expectations: onset, duration, monitoring needs, and common side effects.
• Review importance of sleep, physical activity, structured routines, and reduced distractions.
• Collaborate with families/schools/employers for environmental supports.
• Address emotional health, stigma, and potential comorbid conditions.

References

1. NICE NG87: Attention Deficit Hyperactivity Disorder — Diagnosis and Management — Link
2. American Academy of Pediatrics Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of ADHD in Children and Adolescents (2019) — Link
3. Faraone SV et al. The World Federation of ADHD International Consensus Statement: 208 Evidence-Based Conclusions About ADHD. Neurosci Biobehav Rev. 2021. — Link